MPharma 's growth engine: how it hit 40% MoM growth
The deal, the timing, and who moves next across $Kenya's market.
- The practical move an operator can make this quarter.
- What to watch next as the story develops.
- How Kenya's market shapes the outcome.
The deal, the timing, and who moves next across $Kenya's market.
- The practical move an operator can make this quarter.
- What to watch next as the story develops.
- How Kenya's market shapes the outcome.
For anyone building in marketing & sales, the useful question is where this changes your costs, distribution or competition — and how soon you act on it.
AI-generated summary. It can miss nuance — read the full story above for the complete picture.
In Lagos, the story of mPharma is becoming a case study in what it takes to digitise SME payments.
What's really being tested here is whether a lending product can survive contact with Kenya's real economy.
Why it matters
Capital buys time; execution buys the market.
The move reframes cash flow for anyone building in Kenya: get the fundamentals right before you scale.
Competitors won't sit still. Expect the banks to respond within the quarter.
What to watch next
- How Kenya's regulators respond over the next two quarters.
- Whether the growth round buys enough runway to reach the next milestone.
- Which rivals move first, and how the banks counter.
The bet is placed. The market will settle it soon enough.
